Author: Customer Service

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA’s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment. Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor...

(CUSIP Nos. 37255B AC3; G38327 AD7 / ISIN Nos. US37255BAC37; USG38327AD78) Bogotá, Colombia, Oct. 16, 2026 (GLOBE NEWSWIRE) — GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), an exempted company incorporated under the laws of Bermuda, today announced the commencement of an offer to purchase for cash any and all of its outstanding 8.750% Senior Notes due 2030 (the “Notes”) (the “Tender Offer”). The Tender Offer is being made upon the terms and subject to the conditions (including the Financing Condition (as defined in the Offer to Purchase)) set forth in the offer to purchase dated October 16, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”). The table below summarizes certain payment terms for the Notes:Description of Security   CUSIP No.   ISIN   Outstanding Principal Amount as...

Bogotá, Colombia, Oct. 16, 2026 (GLOBE NEWSWIRE) — GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), an exempted company incorporated under the laws of Bermuda, today announced that it intends to offer senior notes (the “Notes”), guaranteed by certain subsidiaries of the Company, in a private placement to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Concurrent with the announcement of this proposed offering of Notes, the Company has announced that it is making a cash tender offer to purchase any and all of the Company’s outstanding 8.750%...

Why Abu Dhabi Strategy and New Banking Director Signal Bigger Global Ambition DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians and the Department of Health – Abu Dhabi. While a single compassionate-use...

“The Trillion Dollar AI Bottleneck” to feature Fabric.AI Senior Strategic Advisor James Altucher in a discussion of the technologies needed to support AI’s continued growth NEW YORK, NY, Oct. 16, 2026 (GLOBE NEWSWIRE) — Fabric.AI (Nasdaq: FABC) (“Fabric.AI” or the “Company”), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, today announced that James Altucher, Fabric.AI’s Senior Strategic Advisor, will join Michael Murray, Chief Executive Officer, President and Chairperson of its development partner Kopin Corporation (Nasdaq: KOPN), and AI expert Cortney Harding for a live YouTube “Ask Me Anything” panel. Hosted by Kopin and titled “The Trillion Dollar AI Bottleneck,” the event will stream live from Nasdaq MarketSite in New York City on October 20, 2026, at 11:00...

Adding An Experienced Government and Commercial Security Leader WILMINGTON, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, today announced the appointment of Steve Karoly to the Board of Directors, effective immediately. Steve will replace outgoing CEO Bill Frain, who is leaving the company at the end of October, on the Board. “We are extremely pleased to welcome Steve to the Board of Directors,” said John Percival, Chairman of Liberty Defense. “Steve has strong experience in government and transportation security from his years at TSA, Customs & Border Protection and K2 Security Screening. He brings valuable insights into federal...

ACCLARENT AERA® Eustachian Tube TreatmentSimulation of a minimally invasive ear procedure using the ACCLARENT AERA® Eustachian Tube Treatment.PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California. At this year’s meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System. Additionally,...

New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, has identified pancreatic proenzyme formulation, PRP, as a potential strategy for addressing chemotherapy resistance in pancreatic cancer. Chemotherapy-resistant tumor cells can acquire adaptive cellular states that allow them to survive treatment and maintain aggressive characteristics. The study investigated...